Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.47 |
| ▸ | F2 | P00734 | 9/20 | 0.42 |
| ▸ | ERN1 | O75460 | 3/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25035602 | 0.93 | BRAF (0.49) | BRAFF2ERN1F10PRSS1 | |
| SCHEMBL22190942 | 0.89 | ERN1 (0.39) | BRAFF2ERN1PRSS1GLO1 | |
| SCHEMBL29354977 | 0.89 | ERN1 (0.39) | BRAFF2ERN1PRSS1GLO1 | |
| SCHEMBL25035429 | 0.89 | BRAF (0.48) | BRAFF2ERN1F10PRSS1 | |
| SCHEMBL29353158 | 0.89 | ERN1 (0.39) | BRAFF2ERN1GLO1 | |
| SCHEMBL22191003 | 0.89 | ERN1 (0.39) | BRAFF2ERN1GLO1 | |
| SCHEMBL25034178 | 0.86 | BRAF (0.62) | BRAFF2 | |
| SCHEMBL25035525 | 0.85 | BRAF (0.51) | BRAFF2F10PRSS1 | |
| SCHEMBL25035620 | 0.82 | BRAF (0.49) | BRAFF2F10PRSS1 | |
| SCHEMBL25035419 | 0.82 | BRAF (0.46) | BRAFF2ERN1F10PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | BRAF 563/4885F2 1649/4885ERN1 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.